More than 15 years after the introduction of highly active antiretroviral therapy, HIV/HAART-
associated lipodystrophy syndrome still shadows the indisputable efficacy of antiretroviral …

'Lipodystrophy syndrome'in the setting of HIV infection has come to encompass a collection
of morphological and metabolic abnormalities linked with the use of antiretroviral therapy …

Lack of adipose tissue, either complete or partial, is the hallmark of disorders known as
lipodystrophies. Patients with lipodystrophies suffer from metabolic complications similar to …

Highly active antiretroviral therapy (HAART) for human immunodeficiency virus‐1 (HIV‐1)
and prophylactic therapy for opportunistic infections have increased survival. Adverse effects …

Genetic lipodystrophic syndromes are rare diseases characterized by generalized or partial
fat atrophy (lipoatrophy) associated with severe metabolic complications such as insulin …

Lipodystrophies belong to the heterogenous group of syndromes in which the primary defect
is a generalized or partial absence of adipose tissue, which may be congenital or acquired …

Lipodystrophies are the result of a range of inherited and acquired causes, but all are
characterized by perturbations in white adipose tissue function and, in many instances, its …

The pathogenesis of lipodystrophy in HIV-infected patients is likely multifactorial, involving
effects of antiretroviral medications, HIV itself, as well as genetic and other host factors …

Lipoatrophy is perhaps the most visibly recognisable component of antiretroviral-therapy-
associated lipodystrophy due to the rarity of this form of body composition change in the …